Vertex Pharmaceutical Incorporated

Patent Applications and Registrations

Patent applications and USPTO patent grants for Vertex Pharmaceutical Incorporated.The latest application filed is for "therapeutic regimen comprising peg-interferon, ribavirin and vx-950 for the treatment of hepatitis".

Company Profile

1.20.2

Vertex Pharmaceutical Incorporated - Boston MA
Vertex Pharmaceutical Incorporated - Cambridge MA
Vertex Pharmaceutical, Inc. - Cambridge MA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
DNA-PK inhibitors Grant 10,258,627 - Maxwell , et al.	2019-04-16
Method for identifying protease inhibitors Grant 8,501,426 - Taylor August 6, 2	2013-08-06
Process for making modulators of cystic fibrosis transmembrane conductance regulator Grant 8,476,442 - DeMattei , et al. July 2, 2	2013-07-02
Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline- -3-carboxamide Grant 8,471,029 - Arekar , et al. June 25, 2	2013-06-25
Solid forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluorormethyl)phenyl)-4-oxo-5- -(trifluoromethyl)-1,4-dihyroquinoline-3-carboxamide Grant 8,436,014 - Zhang , et al. May 7, 2	2013-05-07
Modulators of ATP-binding cassette transporters Grant 8,431,605 - Hadida Ruah , et al. April 30, 2	2013-04-30
Therapeutic Regimen Comprising Peg-interferon, Ribavirin And Vx-950 For The Treatment Of Hepatitis App 20130101554 - KAUFFMAN; ROBERT S. ; et al.	2013-04-25
Modulators of muscarinic receptors Grant 8,367,691 - Makings , et al. February 5, 2	2013-02-05
Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline- -3-carboxamide Grant 8,362,253 - DeMattei , et al. January 29, 2	2013-01-29
Modulators of ATP-binding cassette transporters Grant 8,354,427 - Van Goor January 15, 2	2013-01-15
Process for preparing modulators of cystic fibrosis transmembrane conductance regulator Grant 8,344,147 - Ambhaikar , et al. January 1, 2	2013-01-01
Modulators of ATP-binding cassette transporters Grant 8,324,242 - Ruah , et al. December 4, 2	2012-12-04
Modulators of cystic fibrosis transmembrane conductance regulator Grant 8,314,239 - Binch , et al. November 20, 2	2012-11-20
Modulators of muscarinic receptors Grant 8,304,423 - Davies , et al. November 6, 2	2012-11-06
Processes for producing phenyl-6-(1-(phenyl)ureido)nicotinamides Grant 8,273,896 - Roeper , et al. September 25, 2	2012-09-25
Modulators of muscarinic receptors Grant 8,263,605 - Makings , et al. September 11, 2	2012-09-11
Spiroindoline modulators of muscarinic receptors Grant 8,258,148 - Makings , et al. September 4, 2	2012-09-04
Pyridyl derivatives as CFTR modulators Grant 8,227,615 - Hadida-Ruah , et al. July 24, 2	2012-07-24
Caspase inhibitors and uses thereof Grant 7,517,987 - Golec , et al. April 14, 2	2009-04-14
Prodrugs of carbamate inhibitors of IMPDH App 20090093639 - Stamos; Dean P. ; et al.	2009-04-09
Inhibitors of aspartyl protease Grant 6,878,728 - Hale , et al. April 12, 2	2005-04-12
Inhibitors of interleukin-1.beta. converting enzyme Grant 6,350,741 - Golec , et al. February 26, 2	2002-02-26

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.